Phase 3 Trial of Agalsidase Beta in Pediatric Patients with Fabry Disease

Andrew Black
Published Online: Monday, Feb 20, 2017
A Phase 3b clinical trial assessing agalsidase beta in lowering pediatric Fabry patient’s globotriaosylceramide [GL-3] levels in skin, plasma and urine showed encouraging results for treatment.
The trial was a Phase 3b randomized, open-label, parallel-group study assessing agalsidase beta in ERT-naive male Fabry patients aged 5-18 years old. Skin biopsies were obtained at ERT-baseline at years 1, 3 and 5, or at early withdrawal.
 Patients were administered at low dose regimens, i.e. 0.5 mg/kg every 2 weeks (0.5q2w, n=16) or 1.0 mg/kg every 4 weeks (1.0q4w, n=15) for 5 years.


13 out of 20 (65%) patients with a non-zero superficial skin capillary endothelium (SSCE) GL-3 score at baseline reached and maintained zero scores (7 on 0.5q2w, 6 on 1.0q4w).
Shifts from baseline non-zero to zero SSCE GL-3 scores were statistically significant at each time point in the overall study population and both treatment groups, except at year 5 in the 1.0q4w group.
No patient had severe SSCE GL-3 accumulation (score of 3) at any time point. All patients with IgG peak titer ≤6400 showed complete and sustained GL-3 clearance in SSCE.
Patients with the highest peak IgG titers tended to show less robust GL-3 clearance in SSCE.


About agalsidase beta

Agalsidase beta is a recombinant human α-galactosidase A enzyme with the same amino acid sequence as the native enzyme.


Ramaswami U, et al. A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from superficial skin capillary endothelium. Presented at 13th Annual WORLDSymposium; February 13-17, 2017; San Diego, CA.

About Fabry disease

Fabry disease is an X-linked lysosomal storage disorder that leads to excessive deposition of globotriaosylceramide (GL-3) throughout the body. Skin, eye, kidney, heart, brain, and peripheral nervous system are highly vulnerable.
The condition is caused by deficiency of the enzyme alpha-galactosidase A (alpha-Gal A) which degrades GL-3. The accumulation of GL-3 is believed to cause a variety of symptoms, including pain, kidney failure, and increased risk of heart attack and stroke.

Latest Articles
Last month, Steve placed first in his division. Two days later, he was busy training for the next contest (May 2017).
Today, the American Health Care Act (aka TrumpCare) is being voted in Congress. The bill needs 215 votes to be approved. It is likely that no Democrats support it, meaning that only 21 Republicans can vote against the bill and it can still get approved.
PANDAS, or pediatric acute-onset neuropsychiatric syndrome, links the sudden onset of OCD or tic-like symptoms to streptococcal-A (GABHS). Could this mysterious affliction be a rare disease or not a disease at all?
To celebrate Rare Disease Day on February 28, 2017, Amicus Therapeutics hosted CabaRare at their Cranbury, N.J. headquarters in which four young people with rare diseases shared their musical talents
$vacMongoViewPlus$ $vAR$